Q4 sales and 2025 guidance exceeded expectations
06/02/25 -"The Q4 sales were ahead of the consensus, though operating profits were somewhat behind the street’s expectations. Also, a better-than-expected 2025 outlook was well received by the markets. ..."
Pages
70
Language
English
Published on
06/02/25
You may also be interested by these reports :
30/10/26
Investors hailed the Q3 profitability beat and the announcement of a cost savings initiative. The generic erosion of some CVRM medicines was ...
30/10/26
The Q3 beat was impressive and a guidance upgrade to boot cheered up investors. As usual, the all-important immunology medicine Dupixent remained a ...
29/10/26
The Q3 EBITDA was somewhat ahead of expectations, unlike sales. While lower demand in Spain and loss of exclusivity in Japan impaired Bilastine’s ...
29/10/26
After increasing both our DCF and NAV estimates by >20% (discussed in the respective sections), we maintain a Reduce recommendation with c.2% ...